Analyzing Efficacy and Safety of Ustekinumab in Prediatric Crohn Disease
The following is a summary of "Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN" published in the December 2022 issue of Gastroenterology by Yerushalmy-Feler et al. Although there were no data for children, increasing the maintenance
Porto Group Potential Efficacy Escalating Dose Pediatric Crohn Disease Speed Up Study Multicenter Study
Source: physiciansweekly.com